ABUS
Arbutus Biopharma Corp

16,880
Loading...
Loading...
News
all
press releases
Is Arbutus Biopharma (ABUS) Stock Outpacing Its Medical Peers This Year?
Here is how Arbutus Biopharma (ABUS) and Armata Pharmaceuticals, Inc. (ARMP) have performed compared to their sector so far this year.
Zacks·11d ago
News Placeholder
More News
News Placeholder
Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?
Here is how Aquestive Therapeutics (AQST) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.
Zacks·29d ago
News Placeholder
Arbutus Biopharma (ABUS) Beats Q2 Earnings and Revenue Estimates
Arbutus (ABUS) delivered earnings and revenue surprises of +150.00% and +496.61%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates
Zacks·4mo ago
News Placeholder
Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates
Zacks·4mo ago
News Placeholder
Is Editas Medicine (EDIT) Stock Outpacing Its Medical Peers This Year?
Zacks·4mo ago
News Placeholder
Cramer+apos;s Lightning Round: Arbutus Biopharma is +apos;the ultimate spec+apos;
"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed...
CNBC: Mad Money with Jim Cramer·8mo ago
News Placeholder
Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value
Whitefort Capital Management, LP (together with its affiliates, Whitefort Capital, us or we), which is a long-term investor and the second largest shareholder of Arbutus Biopharma Corp. (NASDAQ...
Business Wire·1y ago
News Placeholder
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
WARMINSTER, Pa., April 04, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a...
Globe Newswire·1y ago
News Placeholder
Arbutus Biopharma (NASDAQ:ABUS) Share Price Passes Above Two Hundred Day Moving Average of $2.24
Arbutus Biopharma Co. (NASDAQ:ABUS Get Free Report) shares passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $2.24 and traded as...
Zolmax·1y ago

Latest ABUS News

View

Advertisement. Remove ads.

Advertisement. Remove ads.